These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 16885839)
21. Drug-induced nail abnormalities. Piraccini BM; Iorizzo M; Tosti A Am J Clin Dermatol; 2003; 4(1):31-7. PubMed ID: 12477371 [TBL] [Abstract][Full Text] [Related]
22. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction. Paoletti E; Ratto E; Bellino D; Marsano L; Cassottana P; Cannella G J Nephrol; 2012; 25(5):709-18. PubMed ID: 22038336 [TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Ettenger RB; Grimm EM Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S22-8. PubMed ID: 11583941 [TBL] [Abstract][Full Text] [Related]
24. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Groetzner J; Meiser B; Landwehr P; Buehse L; Mueller M; Kaczmarek I; Vogeser M; Daebritz S; Ueberfuhr P; Reichart B Transplantation; 2004 Feb; 77(4):568-74. PubMed ID: 15084937 [TBL] [Abstract][Full Text] [Related]
25. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Baboolal K Transplantation; 2003 Apr; 75(8):1404-8. PubMed ID: 12717239 [TBL] [Abstract][Full Text] [Related]
26. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant. Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086 [TBL] [Abstract][Full Text] [Related]
28. The incidence of cancer and potential role of sirolimus immunosuppression conversion on mortality among a single-center renal transplantation cohort of 1,816 patients. Branco F; Cavadas V; Osório L; Carvalho F; Martins L; Dias L; Castro-Henriques A; Lima E Transplant Proc; 2011; 43(1):137-41. PubMed ID: 21335171 [TBL] [Abstract][Full Text] [Related]
29. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Morelon E; Stern M; Israël-Biet D; Correas JM; Danel C; Mamzer-Bruneel MF; Peraldi MN; Kreis H Transplantation; 2001 Sep; 72(5):787-90. PubMed ID: 11571438 [TBL] [Abstract][Full Text] [Related]
30. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation. Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219 [TBL] [Abstract][Full Text] [Related]
31. Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens. Kirby S; Satoskar A; Brodsky S; Pope-Harman A; Nunley D; Hitchcock C; Pelletier R; Ross P; Nadasdy T; Shilo K Diagn Pathol; 2012 Mar; 7():25. PubMed ID: 22416975 [TBL] [Abstract][Full Text] [Related]
32. Successful treatment of ileal ulcers caused by immunosuppressants in two organ transplant recipients. Guo YW; Gu HY; Abassa KK; Lin XY; Wei XQ World J Gastroenterol; 2016 Jun; 22(24):5616-22. PubMed ID: 27350740 [TBL] [Abstract][Full Text] [Related]
33. Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. Hricik DE; Anton HA; Knauss TC; Rodriguez V; Seaman D; Siegel C; Valente J; Schulak JA Transplantation; 2002 Jul; 74(2):189-93. PubMed ID: 12151730 [TBL] [Abstract][Full Text] [Related]